Leukemia: all 5,475 studies

Page 33 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
• Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
• 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaWithdrawnNCT02472626Phase 1/2
• Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia PatientsSuspendedNCT02462265Phase 2
• Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02461316
• HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-riskCompletedNCT02461121Phase 3
• Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesStatus unknownNCT02456350Phase 1
• An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®TerminatedNCT02455024
• A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
• Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During InductionStatus unknownNCT02451774Phase 2/3
• Fungemia in Hematologic MalignanciesCompletedNCT02451592
• Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA GenotypesActive, not recruitingNCT02450708Not applicable
• Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT02447666Phase 2
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute LeukemiaCompletedNCT02446964Phase 1
• CML Treated With Bosutinib After RelapseCompletedNCT02445742Phase 2
• Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing ChemotherapyCompletedNCT02445378Not applicable
• Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Approved for marketingNCT02437019
• iCare for Cancer PatientsTerminatedNCT02435550Not applicable
• Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years OldStatus unknownNCT02432911Not applicable
• Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 YearsStatus unknownNCT02432872Not applicable
• Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)TerminatedNCT02428517
• Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknownNCT02422719Phase 2
• Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)WithdrawnNCT02421926
• Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2
• The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy RegimensStatus unknownNCT02413021Phase 1
• DC Vaccination for Post-remission Therapy in AMLCompletedNCT02405338Phase 1/2
• A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1
• Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
• Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry StudyCompletedNCT02389972
• Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to DasatinibStatus unknownNCT02389920Phase 4
• Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
• Observational Study in CLL Patients Receiving BRCompletedNCT02381899
• A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
• Malaysia Stop Tyrosine Kinase Inhibitor TrialStatus unknownNCT02381379Phase 3
• Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyCompletedNCT02381080Phase 1
• Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk DiseaseCompletedNCT02378701
• Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell TherapyCompletedNCT02374333Phase 1
• Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic LeukemiaCompletedNCT02373579Phase 2
• Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
• Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare PopulationCompletedNCT02363868
• Vincristine PK and PD in the AYA Population Compared to Younger ChildrenStatus unknownNCT02360930
• Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute LeukemiaCompletedNCT02353559Not applicable
• A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and LymphomaStatus unknownNCT02349698Phase 1/2
• Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With DasatinibCompletedNCT02348957
• Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute LeukemiaStatus unknownNCT02345915Not applicable
• Phase I Dose Escalation of BAY1143572 in Subjects With Acute LeukemiaCompletedNCT02345382Phase 1
• Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute LeukemiaStatus unknownNCT02344966
• The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled StudyCompletedNCT02343965Not applicable
• A Pilot RCT of the PRISM Intervention for AYAs With CancerCompletedNCT02340884Phase 2
• Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in ChildrenStatus unknownNCT02339350Phase 2
• Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesStatus unknownNCT02338479
• Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT02338050Phase 2
• Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell TransplantationCompletedNCT02337595Phase 1/2
• A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and ComorbiditiesTerminatedNCT02336048Phase 1
• First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
• Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
• IFN-DLI for Relapsed Acute Leukemia After Allo-SCTCompletedNCT02331706Early Phase 1
• A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic SyndromeStatus unknownNCT02328950
• Prophylactic Infusion of Donor Lymphocytes in Cord Blood TransplantationCompletedNCT02328885Phase 1/2
• A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLCompletedNCT02326584Phase 1
• Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
• Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 MutationsCompletedNCT02323607Phase 1
• Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3
• Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
• Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
• Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02316964Phase 1
• Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedNCT02316197Phase 1
• Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative TherapyNo longer availableNCT02312037
• Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2
• Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a DatabaseTerminatedNCT02309333
• A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT02308761Phase 1
• Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AMLCompletedNCT02306291Phase 1/2
• A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)WithdrawnNCT02303782Phase 1/2
• Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)CompletedNCT02303522
• Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02299518Phase 1
• Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
• Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance ChemotherapyCompletedNCT02295839Not applicable
• Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTCompletedNCT02294552Phase 2
• Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaCompletedNCT02293109Phase 1
• Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's TransformationWithdrawnNCT02285244Phase 2
• 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)CompletedNCT02283190Phase 1
• Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid LeukemiaCompletedNCT02282215Phase 2
• Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
• Cord Blood Natural Killer (NK) Cells in Leukemia/LymphomaCompletedNCT02280525Phase 1
• Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid LeukaemiaStatus unknownNCT02277847Phase 4
• Observational Trial of a Therapeutic Platelet Transfusion RegimenTerminatedNCT02276651
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
• Study of TCP-ATRA for Adult Patients With AML and MDSCompletedNCT02273102Phase 1
• The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic LeukemiaCompletedNCT02272673
• Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsStatus unknownNCT02272478Phase 2/3
• Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic ImpairmentWithdrawnNCT02269579Phase 2
• A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSTerminatedNCT02267863Phase 1
• Tissue Collection for Biomarkers Determining Resistance to IbrutinibStatus unknownNCT02267590
• Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
• Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
• Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
• Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic TransplantationNo longer availableNCT02258490
• Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AMLTerminatedNCT02255162Phase 1
• Exercise and Quality of Life in Leukemia PatientsCompletedNCT02246907Not applicable
• Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic LeukemiaStatus unknownNCT02244658Phase 3

← Leukemia overview